Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CASTLE-VT: Preventive Ablation in End-Stage Heart Failure
NCT06556485Recruiting
- Sponsor
- Heart and Diabetes Center North Rhine-Westphalia
- Start
- Sep 2024
- Primary completion
- Jun 2026
- Countries
- 1
01
Overview
Randomised, open-label trial (2 arms), sponsored by Heart and Diabetes Center North Rhine-Westphalia. Primary endpoint: Composite of all-cause mortality, worsening of HF requiring prioritized transplantation or LVAD implantation at 2 years. Started Sep 2024; status: recruiting.
Beyond the preview
Go deeper on NCT06556485.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06556485.